Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
0.2093
+0.0035 (1.70%)
Apr 1, 2026, 11:28 AM EDT - Market open
Outlook Therapeutics Revenue
Outlook Therapeutics had revenue of $-1.21M in the quarter ending December 31, 2025. This brings the company's revenue in the last twelve months to $205.70K. In the fiscal year ending September 30, 2025, Outlook Therapeutics had annual revenue of $1.41M.
Revenue (ttm)
$205.70K
Revenue Growth
n/a
P/S Ratio
104.66
Revenue / Employee
$12,100
Employees
17
Market Cap
21.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 1.41M | - | - |
| Sep 30, 2024 | - | - | - |
| Sep 30, 2023 | - | - | - |
| Sep 30, 2022 | - | - | - |
| Sep 30, 2021 | - | - | - |
| Sep 30, 2020 | - | - | - |
| Sep 30, 2019 | 8.15M | 5.06M | 163.84% |
| Sep 30, 2018 | 3.09M | -723.96K | -18.99% |
| Sep 30, 2017 | 3.81M | 831.94K | 27.92% |
| Sep 30, 2016 | 2.98M | -2.24M | -42.91% |
| Sep 30, 2015 | 5.22M | -3.83M | -42.33% |
| Sep 30, 2014 | 9.05M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cue Biopharma | 27.47M |
| Neuphoria Therapeutics | 14.99M |
| Barinthus Biotherapeutics | 14.97M |
| Curis | 9.44M |
| Marker Therapeutics | 3.55M |
| Vistagen Therapeutics | 789.00K |
| VYNE Therapeutics | 570.00K |
OTLK News
- 6 days ago - Outlook Therapeutics Announces Closing of $5.0 Million Public Offering - GlobeNewsWire
- 8 days ago - Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering - GlobeNewsWire
- 8 days ago - Outlook Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 16 days ago - Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note - GlobeNewsWire
- 26 days ago - Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg) - GlobeNewsWire
- 5 weeks ago - Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland - GlobeNewsWire
- 6 weeks ago - Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter - GlobeNewsWire